XML 24 R10.htm IDEA: XBRL DOCUMENT
v3.25.2

Segmentation of key figures | 6 Months Ended
--- | ---
Jun. 30, 2025
Operating Segments [Abstract] |
Segmentation of key figures | Segmentation of key figures The segment information disclosed in these Condensed Consolidated Interim Financial Statements reflects historical results consistent with the identifiable reportable segments of Alcon and financial information that the Chief Operating Decision Maker ("CODM") reviews to evaluate segmental performance and allocate resources among the segments. The CODM is the Executive Committee of Alcon. The businesses of Alcon are divided operationally on a worldwide basis into two identified reportable segments, Surgical and Vision Care. Alcon's reportable segments are the same as its operating segments as Alcon does not aggregate any operating segments in arriving at its reportable segments. As indicated below, certain income and expenses are not allocated to segments. Reportable segments are presented in a manner consistent with the internal reporting to the CODM. The reportable segments are managed separately due to their distinct needs and activities for research, development, manufacturing, distribution and commercial execution. The Executive Committee of Alcon is responsible for allocating resources and assessing the performance of the reportable segments. In Surgical, Alcon researches, develops, manufactures, distributes and sells ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio also includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end procedure needs of the ophthalmic surgeon. In Vision Care, Alcon researches, develops, manufactures, distributes and sells daily disposable, reusable, and color-enhancing contact lenses, cell therapies to treat ocular diseases and a comprehensive portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma and contact lens care, as well as ocular vitamins and redness relievers. Alcon also provides services, training, education and technical support for both the Surgical and Vision Care businesses. The basis of preparation and the selected accounting policies mentioned in Note 1 are used in the reporting of segment results. The Executive Committee of Alcon evaluates segmental performance and allocates resources among the segments based on net sales and segment contribution, which is the single measure of segment profitability. Net identifiable assets are not assigned to the segments in the internal reporting to the CODM, and are not considered in evaluating the performance of the business segments by the Executive Committee of Alcon. Segment contribution excludes amortization and impairment charges for acquired product rights or other intangibles, general and administrative expenses for corporate activities, fair value adjustments to contingent consideration liabilities, past service costs primarily for post-employment benefit plan amendments, acquisition and integration related costs, certain acquisition and divestment related items, product discontinuation costs, fair value adjustments of financial assets in the form of options to acquire a company carried at fair value through profit and loss ("FVPL"), net gains and losses on fund investments and equity securities valued at FVPL, fair value remeasurements of investments in associated companies, restructuring costs, legal provisions and settlements and other income and expense items not attributed to a specific segment. Net sales and other revenues by segment
|  | Three months ended June 30 |  | Six months ended June 30
($ millions) |  | 2025 | 2024 |  | 2025 | 2024
Surgical |  |  |  |  |  |
Implantables |  | 456 |  | 464 |  |  | 876 |  | 897 |
Consumables |  | 777 |  | 736 |  |  | 1,489 |  | 1,422 |
Equipment/other |  | 222 |  | 223 |  |  | 421 |  | 442 |
Total Surgical net sales |  | 1,455 |  | 1,423 |  |  | 2,786 |  | 2,761 |
Vision Care |  |  |  |  |  |
Contact lenses |  | 692 |  | 636 |  |  | 1,380 |  | 1,307 |
Ocular health |  | 430 |  | 423 |  |  | 862 |  | 858 |
Total Vision Care net sales |  | 1,122 |  | 1,059 |  |  | 2,242 |  | 2,165 |
Total net sales |  | 2,577 |  | 2,482 |  |  | 5,028 |  | 4,926 |
Surgical other revenues |  | — |  | — |  |  | 1 |  | — |
Vision Care other revenues |  | 19 |  | 14 |  |  | 40 |  | 29 |
Total other revenues |  | 19 |  | 14 |  |  | 41 |  | 29 |
Total net sales and other revenues |  | 2,596 |  | 2,496 |  |  | 5,069 | 4,955 |
Segment contribution and reconciliation to income before taxes The below tables summarize segment contribution, including material items of income and expense as required by IFRS 8, Operating Segments, and the associated IFRIC agenda decision published in July 2024. The below tables also include a reconciliation of segment contribution to Income before taxes.
| Surgical |  | Vision Care |  | Not allocated to segments |  | Total
| Three months ended June 30 |  | Three months ended June 30 |  | Three months ended June 30 |  | Three months ended June 30
($ millions) | 2025 | 2024 |  | 2025 | 2024 |  | 2025 | 2024 |  | 2025 | 2024
Net sales | 1,455 |  | 1,423 |  |  | 1,122 |  | 1,059 |  |  | — |  | — |  |  | 2,577 |  | 2,482 |
Other revenues | — |  | — |  |  | 19 |  | 14 |  |  | — |  | — |  |  | 19 |  | 14 |
Cost of net sales | (553) |  | (510) |  |  | (416) |  | (422) |  |  | (227) |  | (176) |  |  | (1,196) |  | (1,108) |
Cost of other revenues | — |  | — |  |  | (12) |  | (14) |  |  | — |  | — |  |  | (12) |  | (14) |
Selling, general & administration | (372) |  | (368) |  |  | (415) |  | (390) |  |  | (83) |  | (79) |  |  | (870) |  | (837) |
Research & development | (152) |  | (142) |  |  | (90) |  | (67) |  |  | (3) |  | (11) |  |  | (245) |  | (220) |
Other income | — |  | — |  |  | — |  | — |  |  | 5 |  | 5 |  |  | 5 |  | 5 |
Other expense | — |  | — |  |  | — |  | — |  |  | (31) |  | (4) |  |  | (31) |  | (4) |
Segment contribution and Operating income | 378 |  | 403 |  |  | 208 |  | 180 |  |  | (339) |  | (265) |  |  | 247 |  | 318 |
Interest expense |  |  |  |  |  |  | (51) |  | (50) |  |  | (51) |  | (50) |
Other financial income & expense |  |  |  |  |  |  | 4 |  | 12 |  |  | 4 |  | 12 |
Share of (loss) from associated companies |  |  |  |  |  |  | (1) |  | — |  |  | (1) |  | — |
Income before taxes |  |  |  |  |  |  |  |  |  | 199 |  | 280 |
| Surgical |  | Vision Care |  | Not allocated to segments |  | Total
| Six months ended June 30 |  | Six months ended June 30 |  | Six months ended June 30 |  | Six months ended June 30
($ millions) | 2025 | 2024 |  | 2025 | 2024 |  | 2025 | 2024 |  | 2025 | 2024
Net sales | 2,786 |  | 2,761 |  |  | 2,242 |  | 2,165 |  |  | — |  | — |  |  | 5,028 |  | 4,926 |
Other revenues | 1 |  | — |  |  | 40 |  | 29 |  |  | — |  | — |  |  | 41 |  | 29 |
Cost of net sales | (1,049) |  | (980) |  |  | (813) |  | (838) |  |  | (405) |  | (353) |  |  | (2,267) |  | (2,171) |
Cost of other revenues | (1) |  | — |  |  | (30) |  | (28) |  |  | — |  | — |  |  | (31) |  | (28) |
Selling, general & administration | (728) |  | (720) |  |  | (788) |  | (758) |  |  | (167) |  | (161) |  |  | (1,683) |  | (1,639) |
Research & development | (295) |  | (272) |  |  | (162) |  | (132) |  |  | (10) |  | (15) |  |  | (467) |  | (419) |
Other income | — |  | — |  |  | — |  | — |  |  | 154 |  | 11 |  |  | 154 |  | 11 |
Other expense | — |  | — |  |  | — |  | — |  |  | (60) |  | (23) |  |  | (60) |  | (23) |
Segment contribution and Operating income | 714 |  | 789 |  |  | 489 |  | 438 |  |  | (488) |  | (541) |  |  | 715 |  | 686 |
Interest expense |  |  |  |  |  |  | (100) |  | (95) |  |  | (100) |  | (95) |
Other financial income & expense |  |  |  |  |  |  | 13 |  | 24 |  |  | 13 |  | 24 |
Share of (loss) from associated companies |  |  |  |  |  |  | (15) |  | — |  |  | (15) |  | — |
Income before taxes |  |  |  |  |  |  |  |  |  | 613 |  | 615 |
Net sales by region(1)
| Three months ended June 30 |  | Six months ended June 30
($ millions unless indicated otherwise) | 2025 | 2024 |  | 2025 | 2024
United States | 1,160 |  | 45 | % | 1,141 |  | 46 | % |  | 2,297 |  | 46 | % | 2,290 |  | 46 | %
International | 1,417 |  | 55 | % | 1,341 |  | 54 | % |  | 2,731 |  | 54 | % | 2,636 |  | 54 | %
Net sales | 2,577 |  | 100 | % | 2,482 |  | 100 | % |  | 5,028 |  | 100 | % | 4,926 |  | 100 | %
(1) Net sales by location of third-party customer.

X
- Definition Operating Segments [Abstract] + References No definition available. + Details
Name: | alc_OperatingSegmentsAbstract
Namespace Prefix: | alc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration